Esketamine outperforms one of the standard drugs for treatment-resistant major depression

A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.

FDA’s top cancer leaders want to shift how companion diagnostics are regulated

The FDA is recognizing a major disconnect for some new cancer drugs. This idea that each new oncology drug approved is aligned at the time

July 13, 2023

Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application | Psychedelic Invest

The Multidisciplinary Association for Psychedelic Studies (MAPS) and its Public Benefit Corp. arm, MAPS PBC, today published its second Phase 3 study (MAPP2) of MDMA-assisted therapy (MDMA-AT)

September 14, 2023

Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites

A study in Foods journal finds that Croatian sea fennel’s essential oils and hydrolats exhibit significant anti-aging potential, differing chemically and functionally from French sea

February 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.